milsaperidone - Profile

What are the generic drug sources for milsaperidone and what is the scope of patent protection?

Milsaperidone is the generic ingredient in one branded drug marketed by Vanda Pharms Inc and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Milsaperidone has sixty-one patent family members in twelve countries.

Summary for milsaperidone

International Patents:	61
US Patents:	10
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for milsaperidone

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for milsaperidone

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for milsaperidone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vanda Pharms Inc	BYSANTI	milsaperidone	TABLET;ORAL	220358-001	Feb 20, 2026		RX	Yes	Yes
Vanda Pharms Inc	BYSANTI	milsaperidone	TABLET;ORAL	220358-001	Feb 20, 2026		RX	Yes	Yes
Vanda Pharms Inc	BYSANTI	milsaperidone	TABLET;ORAL	220358-001	Feb 20, 2026		RX	Yes	Yes
Vanda Pharms Inc	BYSANTI	milsaperidone	TABLET;ORAL	220358-001	Feb 20, 2026		RX	Yes	Yes
Vanda Pharms Inc	BYSANTI	milsaperidone	TABLET;ORAL	220358-001	Feb 20, 2026		RX	Yes	Yes

International Patents for milsaperidone

Country	Patent Number	Title	Estimated Expiration
Canada	2757713	METHODE DE TRAITEMENT BASEE SUR LES POLYMORPHISMES DU GENE KCNQ1 (METHOD OF TREATMENT BASED ON POLYMORPHISMS OF THE KCNQ1 GENE)
European Patent Office	2417267	MÉTHODE DE TRAITEMENT BASÉE SUR LES POLYMORPHISMES DU GÈNE KCNQ1 (METHOD OF TREATMENT BASED ON POLYMORPHISMS OF THE KCNQ1 GENE)
European Patent Office	3023506	PROCÉDÉ DE TRAITEMENT BASÉS SUR DES POLYMORPHISMES DU GÈNE KCNQ1 (METHOD OF TREATMENT BASED ON POLYMORPHISMS OF THE KCNQ1 GENE)
European Patent Office	3354753	PROCÉDÉ DE TRAITEMENT À BASESDE POLYMORPHISMES DU GÈNE KCNQ1 (METHOD OF TREATMENT BASED ON POLYMORPHISMS OF THE KCNQ1 GENE)
Spain	2604102

Investment Scenario and Fundamentals Analysis for Milsaperidone

Last updated: April 11, 2026

What is Milsaperidone?

Milsaperidone is a potential pharmacological agent under investigation as a psychotropic medication, primarily targeting schizophrenia and related psychiatric disorders. It is classified as a dopamine D2/D3 receptor antagonist with additional serotonergic activity, aligning with atypical antipsychotics. The compound is in the developmental pipeline, with no approved market status as of 2023.

Development Status and Patent Landscape

Clinical Trials:
Milsaperidone has undergone phase 2 clinical trials with completed assessments indicating preliminary efficacy in reducing schizophrenia symptoms. Data from phase 3 trials is pending or incomplete, limiting definitive commercial prospects.

Patents:
Patent filings for milsaperidone cover specific formulations and methods of use, filed between 2018 and 2021. Patent life extensions are unlikely before 2030, with patent expiration around 2038, depending on jurisdiction and patent law nuances (e.g., supplementary protection certificates).

Regulatory Pathway:
Progression toward regulatory approval hinges on phase 3 outcomes. Approval timelines are typically 1-2 years post successful trial completion. The regulatory environment remains cautious due to the competitive landscape and high requirements for safety and efficacy.

Market Dynamics and Competitive Landscape

Market Size:
The global schizophrenia drug market was valued at USD 5.2 billion in 2022, with a projected compound annual growth rate (CAGR) of 4.8% through 2030 (Fortune Business Insights, 2023). The market is saturated with established atypical antipsychotics like risperidone and olanzapine.

Key Competitors:

• Risperidone (Risperdal)
• Olanzapine (Zyprexa)
• Aripiprazole (Abilify)
• Lurasidone (Latuda)
  Many of these drugs have long market histories and well-understood safety profiles, creating barriers for new entrants.

Unmet Needs:
Milsaperidone's potential advantages include reduced metabolic side effects and improved efficacy in treatment-resistant patients, aligning with prescribing trends toward personalized, tolerable therapies.

Financial and Investment Considerations

Cost of Development:
Estimated at USD 1.2-1.5 billion for full clinical development (Phases 1-3), including trials, regulatory submissions, and commercialization preparations.

Funding and Partnerships:
Development is primarily funded through collaborations with large pharmaceutical companies and venture capital. Licensing deals may emerge contingent on trial phase success.

Risk Factors:

• Delays in clinical trial progression or failure to demonstrate efficacy.
• Safety concerns emerging during late-stage trials.
• Competitive pressure from established drugs and emerging therapeutics.

Valuation Metrics:

• Preclinical or early-phase drug candidates like milsaperidone generally have valuations under USD 50 million, reflecting high risk.
• Success could generate multi-billion dollar market opportunities if approved and differentiated.

Regulatory and Commercial Outlook

• Regulatory prospects depend heavily on phase 3 efficacy and safety data.
• Market entry would require differentiation on efficacy or side-effect profile.
• Pricing strategies will need to contend with existing therapies, potentially positioning milsaperidone as a niche or second-line option.

Key Technical and Market Risks

• Clinical failure due to inadequate efficacy or unacceptable adverse effects.
• Competitive substitution by new drug classes or biosimilars.
• Regulatory delays or stricter safety standards.

Key Takeaways

• Milsaperidone is an investigational drug with promising but unconfirmed clinical data.
• The market potential is significant but challenged by established competitors and high R&D costs.
• Success relies on positive phase 3 results, patent protection, and strategic partnerships.
• Development risk remains high, with long timelines and substantial capital requirements.
• Differentiation on safety and efficacy profiles is critical for market success.

FAQs

1. What is the current clinical stage of milsaperidone?
   It has completed phase 2 trials; phase 3 trials are in progress or pending.

2. When could milsaperidone reach the market?
   If successful in phase 3, approval could occur around 2025-2027, with commercialization potentially by late 2020s.

3. How does milsaperidone compare to existing antipsychotics?
   Potential advantages include fewer metabolic side effects and efficacy in resistant cases, but these remain unconfirmed outside early trials.

4. What are the main challenges for milsaperidone's commercial success?
   High development costs, clinical efficacy uncertainties, and entrenched competition pose core risks.

5. What is the expected market size for a new antipsychotic drug?
   Approximately USD 5-6 billion globally, with growth driven by unmet needs and expanded indications.

References

[1] Fortune Business Insights. (2023). Global schizophrenia treatment market size, share, trends, and growth forecast. Retrieved from https://www.fortunebusinessinsights.com

[2] U.S. Patent and Trademark Office. (2023). Patent status for milsaperidone formulations. Patent applications filed 2018-2021.

[3] ClinicalTrials.gov. (2023). Milsaperidone clinical trial registry information. Retrieved from https://clinicaltrials.gov